Skip to Content
Morningstar

Roche Holding AG ROG

Morningstar Rating
Unlock
Stock XSWX Rating as of
CHF 243.30 −0.10 (0.04%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Roche's Pharma Pipeline and Diagnostics Innovation Support a Wide Moat

Karen Andersen

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare giant is in a unique position to guide global health care into a safer, more personalized, and more cost-effective endeavor. Strong information sharing continues between Genentech and Roche researchers, boosting research and development productivity and personalized medicine offerings that take advantage of Roche's diagnostic expertise.

Read Full Report

Price vs Fair Value

View History
ROG is trading at a 769% premium.
Price
CHF 243.40
Fair Value
CHF 868.00
Uncertainty
Low
1-Star Price
CHF 968.29
5-Star Price
CHF 445.10
Economic Moat
Hqltf
Capital Allocation
Dqlpyvfdd

Bulls Say, Bears Say

Bulls

Roche and its innovative U.S. arm Genentech have a solid history of generating blockbuster therapies in oncology, and Roche's pipeline is full of novel candidates, with a particularly large late-stage pipeline.

Bears

Roche's immuno-oncology drug Tecentriq was launched third to market behind Bristol's Opdivo and Merck's Keytruda, raising questions about Roche's innovation.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ROG is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
CHF 243.40
Day Range
CHF 243.20–246.60
52-Week Range
CHF 212.90–277.25
Bid/Ask
CHF 0.00 / CHF 0.00
Market Cap
CHF 193.97 Bil
Volume/Avg
757,877 / 1.3 Mil

Key Statistics

Price/Earnings (Normalized)
12.43
Price/Sales
3.24
Dividend Yield (Trailing)
3.94%
Dividend Yield (Forward)
3.94%
Total Yield
3.94%

Company Profile

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
103,605
Website
https://www.roche.com

Competitors

Valuation

View More
Metric
ROG
MRK
ABBV
Price/Earnings (Normalized)
 12.4357.9914.95
Price/Book Value
 6.627.9036.13
Price/Sales
 3.245.225.34
Price/Cash Flow
 11.9118.3515.44
Price/Earnings
ROG
MRK
ABBV

Financial Strength

Metric
ROG
MRK
ABBV
Quick Ratio
 0.990.680.72
Current Ratio
 1.351.250.94
Interest Coverage
 14.933.973.95
Quick Ratio
ROG
MRK
ABBV

Profitability

Metric
ROG
MRK
ABBV
Return on Assets (Normalized)
 17.03%5.22%14.14%
Return on Equity (Normalized)
 53.42%13.56%172.29%
Return on Invested Capital (Normalized)
 26.30%8.29%27.87%
Return on Assets
ROG
MRK
ABBV
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
NwtyfcggQjvv$808.7 Bil
 Johnson & Johnson
JNJ
PhpyvvzCln$350.6 Bil
 Merck & Co Inc
MRK
BzktnczlFfqw$318.8 Bil
 AbbVie Inc
ABBV
SbzmztjNdjt$289.3 Bil
 AstraZeneca PLC ADR
AZN
RkzpfsdbdVcp$239.2 Bil
 Novartis AG ADR
NVS
PftnhvpQltkr$220.2 Bil
 Roche Holding AG ADR
RHHBY
WmlcwftsnSmv$218.3 Bil
 Amgen Inc
AMGN
DmscvydjgjVffn$166.0 Bil
 Pfizer Inc
PFE
RhzqvhwGrn$157.0 Bil
 Sanofi SA ADR
SNY
FjdzgddcjKnf$122.8 Bil

Sponsor Center